Drug Trial Radar · NCT06474455
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Jul 2, 2024
Primary completion
Jun 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SHR-9839 for InjectionDrug
SHR-9839 for injection.
SHR-A1921 for InjectionDrug
SHR-A1921 for injection.
SHR-A2009 for InjectionDrug
SHR-A2009 for injection.
Almonertinib Mesilate TabletsDrug
Almonertinib Mesilate Tablets.
Pemetrexed Disodium for InjectionDrug
Pemetrexed Disodium for Injection.
Carboplatin for injectionDrug
Carboplatin for injection.
Paclitaxel injectionDrug
Paclitaxel injection.
SHR-1316 InjectionDrug
SHR-1316 injection.
SHR-9839 for Injection (sc)Drug
SHR-9839 for Injection (sc).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicity (DLT) (phase IB)Time frame: 21 days after the first dose was administered to each subject, up to approximately 24 months.
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) and laboratory abnormalities (phase IB)Time frame: Begin from sign the ICF until the end of the safety follow-up period, up to approximately 24 months.
- Objective Response Rate (ORR) (phase II).Time frame: The first treatment lasted until disease progression, up to approximately 24 months.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.